Abstract
Objectives
Phyllanthus niruri has been known as an immunomodulator and also reported to possess an antiviral activity against several RNA viruses, such as hepatitis B virus and hepatitis C virus by inhibiting viral entry and replication. Since the current situation of Coronavirus Disease 2019 (COVID-19) which infected among the world and caused severe disease and high morbidity, it urgently needed to find new agents against COVID-19. Therefore, in silico screening against COVID-19 receptors is carried out as an initial stage of drug discovery by evaluating the activity of phyllanthin and hypophyllanthin, an isolated from Phyllanthus niruri, in inhibiting spike glycoprotein (6LZG) and main protease (5R7Y) which play as target receptors of COVID-19.
Methods
Molegro Virtual Docker 6.0 used to determine the best binding energy through the rerank score which shows the total energy bonds calculation.
Results
Phyllanthin and hypophyllanthin demonstrated to possess greater binding affinity toward the COVID-19 inhibition sites than their native ligand. The rerank score of phyllanthin and hypophyllanthin are lower than the native ligands 6LZG and 5R7Y. This result indicated that phyllanthin and hypophyllanthin have a stronger interaction than the native ligands both in spike glycoprotein (entry inhibitor) and main protease (translation and replication inhibitor).
Conclusions
In conclusion, phyllanthin and hypophyllanthin are predicted to have strong activity against COVID-19 through inhibiting spike glycoprotein and main protease under in silico study. Further research is needed to support the development of P. niruri as inhibitor agents of COVID-19 through bioassay studies.
Funding source: Ministry of Research and Technology, Republic of Indonesia
-
Research funding: This study was supported by the Ministry of Research and Technology, Republic of Indonesia.
-
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
-
Competing interests: The authors declare there is no conflict of interest in this research.
-
Informed consent: Not applicable.
-
Ethical approval: Not applicable.
References
1. Rothan, HA, Byrareddy, SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 2020;109:102433. https://doi.org/10.1016/j.jaut.2020.102433.Search in Google Scholar
2. Overview – WHO coronavirus disease (COVID-19) dashboard. Available from: https://covid19.who.int/ [Accessed 29 Sep 2020].Search in Google Scholar
3. Publication – draft landscape of COVID-19 candidate vaccines. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines [Accessed 11 Oct 2020].Search in Google Scholar
4. Coronavirus disease 2019 (COVID-19) – COVID-19 vaccines. Available from: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines#podcasts-publications [Accessed 11 Oct 2020].Search in Google Scholar
5. Lu, H. Drug treatment option for the 2019-new coronavirus (2019-nCoV). Biosci Trends 2020;4:69–71. https://doi.org/10.5582/bst.2020.01020.Search in Google Scholar
6. Coronavirus disease 2019 (COVID-19) – medical countermeasures. Available from: https://www.fda.gov/emergency-preparedness-and-response/counterterrorism-and-emerging-threats/coronavirus-disease-2019-covid-19#mcms [Accessed 29 Sep 2020].Search in Google Scholar
7. Kumar, A, Choudhir, G, Shukla, SK, Sharma, M, Tyagi, P, Bhushan, A, et al.. Identification of phytochemical inhibitors against main protease of COVID-19 using molecular modeling approaches. J Biomol Struct Dyn 2020;1:11. https://doi.org/10.1080/07391102.2020.1772112 [Epub ahead of print].Search in Google Scholar
8. Mathur, S, Hoskins, C. Drug development: lessons from nature. Biomed Rep 2017;6:612–4. https://doi.org/10.3892/br.2017.909.Search in Google Scholar
9. Kuttan, R, Harikumar, KB, editors. Phyllanthus species: scientific evaluation and medicinal applications. Boca Raton: CRC Press; 2012.10.1201/b11380Search in Google Scholar
10. Seyed, MA. A comprehensive review on Phyllanthus derived natural products as potential chemotherapeutic and immunomodulators for a wide range of human diseases. Biocatal Agric Biotechnol 2019;17:529–37. https://doi.org/10.1016/j.bcab.2019.01.008.Search in Google Scholar
11. Sarisetyaningtyas, PV, Hadinegoro, SR, Munasir, Z. Randomized controlled trial of Phyllanthus niruri Linn extract. Paediatr Indones 2006;46:77–81.10.14238/pi46.2.2006.77-81Search in Google Scholar
12. Azam, M, Ajitha, M. Phyllanthin: a potential lead molecule for the future needs. Int J Pharmacogn Phytochem Res 2017;9:1081–9. https://doi.org/10.25258/phyto.v9i08.9615.Search in Google Scholar
13. Tan, WC, Jaganath, IB, Manikam, R, Sekaran, SD. Evaluation of antiviral activities of four local Malaysian Phyllanthus species against herpes simplex viruses and possible antiviral target. Int J Med Sci 2013;10:1817–29. https://doi.org/10.7150/ijms.6902.Search in Google Scholar
14. Wahyuni, TS, Azmi, D, Permanasari, AA, Adianti, M, Tumewu, L, Widiandani, T, et al.. Anti-viral activity of Phyllanthus niruri against hepatitis C virus. Malays Appl Biol 2019;48:105–11.Search in Google Scholar
15. Wahyuni, TS, Permanasari, AA, Widyawaruyanti, A, Hotta, H, Aoki-Utsubo, C, Hafid, AF. Antiviral activity of Indonesian medicinal plants against hepatitis B virus. Phcog J 2020;12:1108–14. https://doi.org/10.5530/pj.2020.12.157.Search in Google Scholar
16. Lipinski, CA, Lombardo, F, Dominy, BW, Feeney, PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2012;466:3–26.10.1016/j.addr.2012.09.019Search in Google Scholar
17. Mishra, GP, Panigrahi, D. Computational studies of drugs for possible action against Covid-19 infections. J Drug Deliv Therapeut 2020;10:99–105. https://doi.org/10.22270/jddt.v10i6.4381.Search in Google Scholar
18. Pires, DE, Blundell, TL, Ascher, DB. pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J Med Chem 2015;58:4066–72. https://doi.org/10.1021/acs.jmedchem.5b00104.Search in Google Scholar
19. Theory – how to interpret pkCSM results. Available from: http://biosig.unimelb.edu.au/pkcsm/theory [Accessed 13 Oct 2020].Search in Google Scholar
20. Ekor, M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol 2014;4:177. https://doi.org/10.3389/fphar.2013.00177.Search in Google Scholar
21. Panyond, S, Ho, CT, Sheen, LY. Dietary therapy and herbal medicine for COVID-19 prevention: a review and perspective. J Tradit Complementary Med 2020;10:420–7.10.1016/j.jtcme.2020.05.004Search in Google Scholar PubMed PubMed Central
22. Li, H, Liu, SM, Yu, XH, Tang, SL, Tang, CK. Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int J Antimicrob Agents 2020;55:105951. https://doi.org/10.1016/j.ijantimicag.2020.105951.Search in Google Scholar
23. Kannan, S, Shaik Syed Ali, P, Sheeza, A, Hemalatha, K. COVID-19 (novel coronavirus 2019) – recent trends. Eur Rev Med Pharmacol Sci 2020;24:2006–11. https://doi.org/10.26355/eurrev_202002_20378.Search in Google Scholar
24. Zhang, H, Penninger, JM, Li, Y, Zhong, N, Slutsky, AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 2020;46:586–90. https://doi.org/10.1007/s00134-020-05985-9.Search in Google Scholar
25. Gelman, R, Bayatra, A, Kessler, A, Schwartz, A, Ilan, Y. Targeting SARS-CoV-2 receptors as a means for reducing infectivity and improving antiviral and immune response: an algorithm-based method for overcoming resistance to antiviral agents. Emerg Microb Infect 2020;9:1397–406. https://doi.org/10.1080/22221751.2020.1776161.Search in Google Scholar
26. V’kovski, P, Kratzel, A, Steiner, S, Stalder, H, Thiel, V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol 2020 Oct 28. https://doi.org/10.1038/s41579-020-00468-6 [Epub ahead of print].Search in Google Scholar
27. Wang, Q, Zhang, Y, Wu, L, Niu, S, Song, C, Zhang, Z, et al.. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell 2020;181:894–904.e9. https://doi.org/10.1016/j.cell.2020.03.045.Search in Google Scholar
28. Structure 5R7Y PanDDA analysis group deposition – crystal Structure of COVID-19 main protease in complex with Z45617795. Available from: https://www.rcsb.org/structure/5R7Y [Accessed 29 Sep 2020].Search in Google Scholar
29. Cui, W, Yang, K, Yang, H. Recent progress in the drug development targeting SARS-CoV-2 main protease as treatment for COVID-19. Front Mol Biosci 2020 Dec 4. https://doi.org/10.3389/fmolb.2020.616341 [Epub ahead of print].Search in Google Scholar
30. Rodríguez-García, C, Sánchez-Quesada, C, Toledo, E, Delgado-Rodríguez, M, Gaforio, JJ. Naturally lignan-rich foods: a dietary tool for health promotion? Molecules 2019;24:917. https://doi.org/10.3390/molecules24050917.Search in Google Scholar
31. Charlton, JL. Antiviral activity of lignans. J Nat Prod 1998;61:1447–51. https://doi.org/10.1021/np980136z.Search in Google Scholar
32. Zhang, J, Chen, J, Liang, Z, Zhao, C. New lignans and their biological activities. Chem Biodivers 2014;11:1–54. https://doi.org/10.1002/cbdv.201100433.Search in Google Scholar
33. Cui, Q, Du, R, Liu, M, Rong, L. Lignans and their derivatives from plants as antivirals. Molecules 2020;25:183. https://doi.org/10.3390/molecules25010183.Search in Google Scholar
34. Mao, X, Wu, LF, Guo, HL, Chen, WJ, Cui, YP, Qi, Q, et al.. The genus Phyllanthus: an ethnopharmacological, phytochemical, and pharmacological review. Evid base Compl Alternative Med 2016 Apr 20. https://doi.org/10.1155/2016/7584952 [Epub ahead of print].Search in Google Scholar
35. Li, R, Narita, R, Ouda, R, Kimura, C, Nishimura, H, Yatagai, M, et al.. Structure-dependent antiviral activity of catechol derivatives in pyroligneous acid against the encephalomycarditis virus. RSC Adv 2018;8:35888–96. https://doi.org/10.1039/c8ra07096b.Search in Google Scholar
36. Yuandani, Ilangkovan, M, Jantan, I, Mohamad, HF, Husain, K, Abdul Razak, AF. Inhibitory effects of standardized extracts of Phyllanthus amarus and Phyllanthus urinaria and their marker compounds on phagocytic activity of human neutrophils. Evid base Compl Alternative Med 2013 May 2. https://doi.org/10.1155/2013/603634 [Epub ahead of print].Search in Google Scholar
37. Ji Ram, V, Sethi, A, Nath, M, Pratap, R. Chapter 5: five-membered heterocycles. In: Ji Ram, V, Sethi, A, Nath, M, Pratap, R, editors. The chemistry of heterocycles: nomenclature and chemistry of three-to-five membered heterocycles. United Kingdom: Elsevier; 2019.10.1016/B978-0-08-101033-4.00002-4Search in Google Scholar
38. Nguyen-Ba, N, Lee, N, Chan, L, Zacharie, B. Synthesis and antiviral activities of N-9-oxypurine 1,3-dioxolane and 1,3-oxathiolane nucleosides. Bioorg Med Chem Lett 2000;10:2223–6. https://doi.org/10.1016/s0960-894x(00)00452-2.Search in Google Scholar
39. Pollastri, MP. Overview on the rule of five. Curr Protoc Pharmacol 2010;49:9.12.1–8. https://doi.org/10.1002/0471141755.ph0912s49.Search in Google Scholar
© 2021 Walter de Gruyter GmbH, Berlin/Boston
